Skip to main content
HR 4069 113th Congress House Crime and Law Enforcement Advisory bodies Crime prevention Criminal justice information and records Drug trafficking and controlled substances Drug, alcohol, tobacco use Employee hiring Government studies and investigations Internet and video services Internet, web applications, social media Licensing and registrations Prescription drugs Retail and wholesale trades

Ensuring Patient Access and Effective Drug Enforcement Act of 2013

Introduced: February 18, 2014 See on congress.gov
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 7, 2014
Subcommittee Hearings Held.
Mar 20, 2014
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Feb 21, 2014
Referred to the Subcommittee on Health.
Feb 18, 2014
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 18, 2014
Introduced in House
 Plain-English summary Congressional Research Service

Ensuring Patient Access and Effective Drug Enforcement Act of 2013 - Amends the Controlled Substances Act to require registrants to manufacture, distribute, or dispense controlled substances to obtain a criminal background check on, and perform drug testing on, each employee with access to facility areas where controlled substances are stored. Requires such background checks to be obtained when such an employee is hired and periodically thereafter, but not more frequently than every two years. Authorizes registration suspension or revocation and a $10,000 penalty for failing to comply with such requirements.

Requires the Attorney General, before revoking or suspending a registration under such Act, to: (1) provide the registrant notice of the grounds for doing so, and where such grounds consist of a legal violation, a specific citation to such law; (2) give the registrant an opportunity to submit a corrective action plan within a reasonable time period; and (3) determine whether, in light of the plan, revocation or suspension proceedings should be discontinued or deferred or additional changes need to be made in such plan.

Establishes the Combating Prescription Drug Abuse Working Group to: (1) report on federal initiatives to reduce prescription drug diversion and abuse, (2) identify gaps and opportunities to ensure the safe use of prescription drugs with the potential for diversion and abuse, (3) examine recommendations to transfer one or more controlled substances from schedule III to schedule II to evaluate the effectiveness of such a transfer in reducing diversion and abuse and any effect of such a transfer on access to prescription drugs for legitimate medical purposes, (4) make recommendations on specific ways to reduce the diversion and abuse of prescription drugs, and (5) report on its efforts to prevent or reduce prescription drug diversion and abuse to ensure that patients continue to have access to medications.

What's happening now April 7, 2014

Subcommittee Hearings Held.

 Committees of jurisdiction 4